Zymeworks Stock Price, News & Analysis

Zymeworks (NASDAQ: ZYME) reported key developments and financial results for Q4 and full-year 2024. The company achieved significant milestones, including the FDA accelerated approval of Ziihera® for HER2-positive biliary tract cancer and initiation of first-in-human studies for two pipeline products: ZW191 and ZW171.

Financial highlights include $324.2 million in cash resources as of December 31, 2024, with projected runway into 2H-2027. Revenue was $76.3 million in 2024, including a $25 million milestone payment from Jazz for Ziihera's approval. The company reported a net loss of $122.7 million for 2024.

Key pipeline updates include: accelerated IND submission timeline to mid-2025 for ZW251 (targeting GPC3), ongoing Phase 1 trials for ZW191 in FR⍺-expressing tumors and ZW171 in advanced cancers, and paused development of ZW220. Ziihera® achieved initial sales of $1.1 million in December 2024 following FDA approval.

Zymeworks (Nasdaq: ZYME) has announced the achievement of a significant $14 million cash research milestone from its collaboration with GSK. The milestone payment is associated with a clinical achievement in their partnership. Zymeworks, a clinical-stage biotechnology company, focuses on developing novel, multifunctional biotherapeutics aimed at improving treatment standards for challenging conditions including cancer, inflammation, and autoimmune diseases.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics for diseases including cancer, inflammation, and autoimmune disease, has announced its participation in four upcoming investor conferences in March 2025.

The company's management will attend the TD Cowen 45th Annual Health Care Conference in Boston on March 4, presenting at 10:30 am ET. They will also present at the Leerink Global Healthcare Conference in Miami on March 10 at 8:00 am ET.

Additionally, Zymeworks will participate in one-on-one meetings at the Barclays 27th Annual Global Healthcare Conference on March 11 and the Jefferies Biotech on the Beach Summit on March 12, both in Miami, FL.

Zymeworks Inc. (Nasdaq: ZYME) has appointed Oleg Nodelman to its board of directors, effective February 17, 2025. Nodelman, the Founder and Managing Director of EcoR1 Capital, , represents the largest current stockholder of Zymeworks and brings over two decades of investment management experience to the role.

This appointment marks the seventh new director added in the past two years as part of the company's board renewal process. Nodelman, who holds a Bachelor of Science in Foreign Service from Georgetown University, currently serves as a director at Galapagos NV and AnaptysBio. His expertise in business development, capital deployment, and deep connections in the biotech sector position him as a strategic addition to support Zymeworks' mission of developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its fourth quarter and full year 2024 financial results announcement for March 5, 2025, after market close.

The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day, where management will discuss the financial results and provide a corporate update. Investors can access the webcast live and replay through Zymeworks' investor relations website.

Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in three major upcoming investor conferences in February 2025.

The company will be present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, participating in one-on-one meetings and a fireside chat at 11:20 am ET. Management will also join Citi's 2025 Virtual Oncology Leadership Summit for a virtual fireside chat on February 20 at 2:00 pm ET. Additionally, they will attend the B. Riley Securities Precision Oncology & Radiopharma Conference in New York on February 28, engaging in one-on-one meetings and a panel discussion.

Zymeworks (NASDAQ: ZYME) has outlined its strategic priorities for 2025-2026, highlighting significant developments in its pipeline. The company plans to submit IND applications for ZW220 and ZW251 in solid tumors in 2025, followed by ZW209 and ZW1528 in 2026. Phase 3 HERIZON-GEA-01 top-line results for Ziihera® in first-line HER2-positive gastroesophageal adenocarcinoma are expected in Q2-2025.

The company reported approximately $324 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Combined with anticipated regulatory milestone payments, this provides a projected cash runway into the second half of 2027. Key 2024 achievements include FDA approval of Ziihera® for HER2-positive second-line BTC, initiation of first-in-human studies for ZW171 and ZW191, and completion of a $30 million share repurchase program.

Zymeworks (NASDAQ: ZYME) announced significant progress in its oncology programs and expansion into autoimmune and inflammatory diseases during its R&D Day. The company is ahead of schedule in delivering five Investigational New Drug (IND) applications for its solid tumor strategy, achieving this goal 18 months earlier than planned.

Key highlights include the nomination of ZW209, a novel trispecific T cell engager, as the fifth development candidate in their solid tumor portfolio, and ZW1528, their first development candidate for autoimmune and inflammatory diseases, targeting respiratory inflammation in COPD.

The company's pipeline focuses on gynecological, thoracic, and digestive system cancers, with five drug candidates expected to advance into clinical trials by first half of 2026. The expansion leverages their clinically validated Azymetric™ technology platform and expertise in multispecific therapeutics.

Zymeworks (Nasdaq: ZYME) has announced its participation in several upcoming investor conferences in December 2024 and January 2025. The company will attend the Piper Sandler Healthcare Conference, Citi's Global Healthcare Conference, Evercore HealthCONx Conference, and the J.P. Morgan Healthcare Conference.

Additionally, Zymeworks will host a Research & Development Day on December 12, 2024, in New York. Led by Chief Scientific Officer Paul Moore, the event will showcase updates on their solid tumor targeting antibody-drug conjugates and T-cell Engager molecules, announce a candidate nomination from their Trispecific TCE platform, and discuss potential expansion into hematological cancers and autoimmune diseases.